BioCentury
ARTICLE | Clinical News

Enfortumab vedotin: Phase I data

May 30, 2016 7:00 AM UTC

An open-label, dose-escalation, North American Phase I trial in 28 evaluable patients with metastatic urothelial cancer previously treated with >=1 chemotherapy regimen or who were unfit for cisplatin...